MorphoSys AG and Sigma-Aldrich Corporation Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies

MARTINSRIED, Germany, Feb. 27, 2008 (PRIME NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment, TecDAX) and Sigma-Aldrich (Nasdaq:SIAL) today announced a collaboration agreement to design, produce and distribute unique recombinant research antibodies using MorphoSys’s proprietary HuCAL GOLD technology. MorphoSys’s AbD Serotec unit will develop and qualify unique antibodies from MorphoSys’s proprietary HuCAL GOLD library against a committed number of targets identified and supplied by Sigma-Aldrich. HuCAL GOLD is the most recent and most powerful phage-display library developed for the in vitro generation of highly specific and fully human antibodies. The large diversity of the library guarantees fast and successful generation of high-quality antibodies to targets that have previously been difficult to probe with standard antibody-generation technologies. Sigma-Aldrich will offer the HuCAL-based recombinant research antibodies for use in research applications through its powerful and unique online sales platforms Antibody Explorer(tm) and Your Favorite Gene Search(tm).

MORE ON THIS TOPIC